Welcome to our dedicated page for Takeda Pharm SEC filings (Ticker: TAK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Takeda Pharmaceutical Company Limited American Depositary Shares (NYSE: TAK) on Stock Titan provides access to the company’s U.S. regulatory disclosures, primarily furnished on Form 20-F and Form 6-K as a foreign private issuer. Takeda prepares its consolidated financial statements in accordance with International Financial Reporting Standards (IFRS) and uses these filings to report semi-annual and annual results, management guidance and material developments in its business.
Recent Form 6-K submissions include English translations of Takeda’s semi-annual securities report and earnings report (Kessan Tanshin) for the six-month period ended September 30, 2025. These documents present revenue by business area (Gastroenterology, Rare Diseases, Plasma-Derived Therapies, Oncology, Vaccines, Neuroscience and Other) and by geographic region, along with operating profit, net profit, cash flow information and explanations of non-IFRS core measures such as core revenue, core operating profit and core EPS. They also discuss factors affecting performance, including generic erosion of specific products, foreign exchange impacts and changes in product mix.
Takeda’s 6-K filings additionally furnish press releases that describe key R&D and strategic events, such as Phase 3 data for zasocitinib (TAK-279) in plaque psoriasis, longer-term VERIFY and THRIVE results for rusfertide in polycythemia vera, portfolio decisions like discontinuation of cell therapy efforts, and revised forecasts for FY2025 revenue and profit. These exhibits provide context on how clinical outcomes, impairments of intangible assets and strategic partnerships influence Takeda’s financial outlook.
Through Stock Titan, users can review Takeda’s SEC filings as they are posted, while AI-powered tools can help summarize lengthy IFRS financial reports, highlight changes in management guidance, and surface important disclosures related to pipeline programs, impairments, capital allocation and regional performance. This makes it easier to understand how Takeda’s global biopharmaceutical operations and late-stage pipeline are reflected in its official U.S. regulatory documents.
TAKEDA PHARMACEUTICAL CO LTD director Ian T. Clark filed an initial ownership report showing his existing equity interests in the company. The filing lists direct holdings of 9,696 American Depositary Shares and 9,700 Ordinary Shares, along with several equity-based awards.
These include "Tax Obligation Awards" economically equivalent to Ordinary Shares that will be settled in cash primarily to cover tax obligations, and a cash-settled retirement RSU award tied to the value of 2,356 Ordinary Shares. Additional RSU grants are scheduled to vest in tranches on June 1, 2026, June 1, 2027 and June 1, 2028, with each unit linked to one Ordinary Share and converting into American Depositary Shares upon vesting.
Takeda Pharmaceutical Co. Ltd. director Steven Gillis filed an initial Form 3 reporting his beneficial holdings. He directly holds 9,700 Ordinary Shares and 15,857 American Depositary Shares.
He also reports several equity-based awards. Tax Obligation Awards are each economically equivalent to one Ordinary Share and, upon vesting, will be settled in cash primarily to cover tax obligations at the then-current market price of the Ordinary Shares. A separate Cash Settled Retirement Award consists of restricted stock units that pay cash equal to the value of one Ordinary Share at vesting, which occurs upon his retirement from the board. Another RSU award will convert into Ordinary Shares, then into an equivalent number of American Depositary Shares as it vests on June 1, 2026 (3,100 Ordinary Shares), June 1, 2027 (3,400 Ordinary Shares) and June 1, 2028 (3,200 Ordinary Shares).
TAKEDA PHARMACEUTICAL CO LTD director and President of R&D Andrew Stewart Plump filed an initial Form 3 reporting his holdings in American Depositary Shares. He reports 594,102 ADS held directly and 281,307 ADS held indirectly through a trust. A footnote states that these figures include 251,962 restricted stock units that convert into ADS as they vest on July 1, 2026, July 1, 2027, and July 1, 2028.
Takeda Pharmaceutical Co Ltd executive Lauren Rusckowski Duprey reports her initial beneficial ownership of 168,513 American Depositary Shares. This includes 86,772 restricted stock units, each representing a right to receive one share. The RSUs vest in stages: 40,668 shares on July 1, 2026, 30,488 on July 1, 2027, and 15,616 on July 1, 2028, reflecting a multi-year equity compensation package aligned with her role as Chief HR Officer.
TAKEDA PHARMACEUTICAL CO LTD director Masami Iijima has filed an initial ownership report. The filing shows direct ownership of 12,801 Ordinary Shares and Tax Obligation Awards linked to 2,152, 2,392 and 2,280 underlying Ordinary Shares. It also notes 6,400 restricted stock units that vest in tranches of 2,100, 2,200 and 2,100 shares on June 1, 2026, 2027 and 2028, respectively. Each Tax Obligation Award is economically equivalent to one Ordinary Share and is settled in cash at vest primarily to cover tax obligations.
TAKEDA PHARMACEUTICAL CO LTD director Koji Hatsukawa filed an initial ownership report showing equity and award holdings in the company. He directly holds 25,834 Ordinary Shares.
He also holds several Tax Obligation Awards, each economically equivalent to one Ordinary Share and intended to be settled in cash at vesting primarily to cover tax obligations. These awards reference 2,152, 2,392, 2,280 and 2,318 underlying Ordinary Shares, with scheduled vesting or expiration dates between June 1, 2026 and June 1, 2028 or upon conclusion of board service.
In addition, the holdings include an award of 8,600 restricted stock units, each representing a contingent right to receive one Ordinary Share. These RSUs vest in tranches of 2,100, 2,200, and 2,100 shares on June 1, 2026, 2027 and 2028, with a final 2,200-share tranche vesting upon retirement from board service.
Takeda Pharmaceutical Company reported that the U.S. FDA has accepted the New Drug Application and granted Priority Review for rusfertide, an investigational first-in-class hepcidin mimetic peptide for adults with polycythemia vera. The agency set a Prescription Drug User Fee Act target action date in the third quarter of this calendar year.
The NDA is primarily supported by the Phase 3 VERIFY study, where rusfertide plus standard of care more than doubled clinical response rates versus standard care alone, as well as four-year efficacy and safety data from Phase 2 REVIVE/THRIVE studies. Rusfertide met its primary and all four key secondary endpoints and was generally well-tolerated, with injection site reactions, anemia and fatigue as the most common adverse events.
Rusfertide has also received Breakthrough Therapy, Orphan Drug and Fast Track designations from the FDA. Takeda states that the impact of the NDA acceptance on its financial results for the fiscal year ending March 31, 2026 is immaterial.
Takeda Pharmaceutical Company Limited filed a Form 6-K highlighting that the U.S. Food and Drug Administration has accepted its New Drug Application and granted Priority Review for oveporexton (TAK-861) to treat narcolepsy type 1, a rare neurological disease driven by orexin loss. Oveporexton is an investigational oral orexin receptor 2-selective agonist designed to restore orexin signaling and address the underlying orexin deficiency that causes narcolepsy type 1.
The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of this calendar year, positioning oveporexton as a potential first-in-class orexin agonist therapy. The application is supported by global Phase 3 FirstLight and RadiantLight studies that showed statistically significant, clinically meaningful improvements across key symptoms and quality-of-life measures, with a generally well-tolerated safety profile. Takeda states that this NDA filing has no significant impact on its full year consolidated forecast for the fiscal year ending March 31, 2026.
Takeda Pharmaceutical Company Limited reported mixed results for the nine months ended December 31, 2025. Revenue fell to JPY 3,411.2 billion, down 3.3% year over year, mainly because its ADHD drug VYVANSE in the U.S. faced heavy generic competition, sharply reducing Neuroscience revenue.
Despite lower sales, cost controls and fewer restructuring charges helped operating profit edge up 1.2% to JPY 422.4 billion, while net profit rose 2.4% to JPY 216.3 billion. Core operating profit and Core EPS declined about 3–4% as Takeda absorbed lower Neuroscience revenue and higher impairments on certain R&D assets.
The balance sheet strengthened, with total assets at JPY 15.4 trillion and the equity ratio improving to 49.6%. Operating cash flow increased to JPY 966.9 billion, supporting ongoing dividends; the company projects a full-year dividend of JPY 200 per share. Management slightly raised FY2025 revenue, operating profit and EPS forecasts, mainly from foreign-exchange tailwinds, but revised Core Revenue guidance to a low-single-digit decline at constant exchange rates.
Takeda reported strong Phase 3 results for its investigational oral psoriasis drug zasocitinib (TAK-279) in adults with moderate-to-severe plaque psoriasis. Two large, randomized, double-blind studies showed zasocitinib was superior to placebo at week 16 on both co-primary goals: static Physician Global Assessment (sPGA 0/1) and Psoriasis Area and Severity Index (PASI 75). All 44 ranked secondary endpoints, including higher bars of PASI 90 and PASI 100 against both placebo and apremilast, were also met.
More than half of treated patients achieved clear or almost clear skin (PASI 90), and on average about 30 percent reached completely clear skin (PASI 100) by week 16, with responses continuing to improve through week 24. Zasocitinib was generally well-tolerated, with common side effects such as upper respiratory infections, nasopharyngitis and acne, and no new safety signals. Takeda plans to submit a New Drug Application to the U.S. Food and Drug Administration and other regulators starting in fiscal year 2026, and currently expects these results to have no significant impact on its full-year forecast for the fiscal year ending March 31, 2026.